×

DiffDx-Melanoma
Clinical Evidence

NOW AVAILABLE: A More Objective and Comprehensive Diagnostic Testing Solution
for Difficult-to-Diagnose Melanocytic Lesions. LEARN MORE

DiffDx Development & Validation

Validation Study 1:

Estrada SI, Shackelton JB, Cleaver NJ, et al. Development and validation of a diagnostic 35-gene expression profile test for ambiguous or difficult-to-diagnose suspicious pigmented skin lesions. SKIN: J Cutan Med 2020;4:506-22.

  • Retrospective cohort (n=503) representing broad range of clinical and histopathologic subtypes
  • Reference standard: Independent concordant diagnosis by 2 out of 3 expert dermatopathologists
  • Sensitivity = 99.1%; Specificity = 94.3%
DiffDx Chart

Clinical Utility Study 1: 

Farberg AS, Ahmed KL, Bailey CN, et al. A 35-gene expression profile test for use in suspicious pigmented lesions impacts clinical management decisions of dermatopathologists and dermatologists. SKIN: J Cutan Med 2020;4:523-33.

  • Retrospective cohort (n=60 as designated as ambiguous)
  • Dermatopathologists utilized the 35-GEP result to refine their diagnoses in lesions receiving a benign vs. malignant 35-GEP result (82.3% diagnostic downgrade vs. 94.9% diagnostic upgrade, respectively). 

Key Findings: Dermatopathologists

 

chart (2)
Graphv5

DiffDx-Melanoma has demonstrated high levels of both sensitivity and specificity with a low rate of intermediate results across a wide range of melanocytic subtypes and high rate of technical success.

melhcp-riskidentified.svg

Order Our Comprehensive Diagnostic Offering

For Information

Call: 866-788-9007

Video Webinar

An introduction to our Comprehensive Diagnostic Offering by Castle Biosciences Medical Director Matthew Goldberg, MD.

Expert Opinions in Melanoma

When Is the myPath Melanoma Test Most Helpful

On-Demand
Educational Programs

What's Next?

Comprehensive Diagnostic Solution Test Process

How Do You Order a
myPath Melanoma and
DiffDx-Melanoma Test?

Scroll to Top